113 related articles for article (PubMed ID: 24068633)
1. 18F-FDGPET/CT: diabetes and hyperglycaemia.
Niccoli-Asabella A; Iuele FI; Merenda N; Pisani AR; Notaristefano A; Rubini G
Nucl Med Rev Cent East Eur; 2013; 16(2):57-61. PubMed ID: 24068633
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET-CT scanning and diabetic patients: what to do?
Martin J; Saleem N
Nucl Med Commun; 2014 Dec; 35(12):1197-203. PubMed ID: 25211626
[TBL] [Abstract][Full Text] [Related]
3. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?
Mirpour S; Meteesatien P; Khandani AH
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):71-7. PubMed ID: 22088805
[TBL] [Abstract][Full Text] [Related]
4. Normal variations and benign findings in pediatric 18F-FDG-PET/CT.
Grant FD
PET Clin; 2014 Apr; 9(2):195-208. PubMed ID: 25030282
[TBL] [Abstract][Full Text] [Related]
5. [18F-FDG PET/CT in ocular and orbital abnormalities not only neopastic: comparison with traditional imaging].
Altini C; Niccoli Asabella A; Ferrari C; Rubini D; Merenda N; Rubini G
Recenti Prog Med; 2015 Aug; 106(8):393-401. PubMed ID: 26228862
[TBL] [Abstract][Full Text] [Related]
6. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
7. Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET/CT studies.
Garcia JR; Sanchis A; Juan J; Tomas J; Domenech A; Soler M; Moragas M; Riera E
Nucl Med Commun; 2014 May; 35(5):459-65. PubMed ID: 24535382
[TBL] [Abstract][Full Text] [Related]
8. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
9. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients.
Roy FN; Beaulieu S; Boucher L; Bourdeau I; Cohade C
J Nucl Med; 2009 Feb; 50(2):178-83. PubMed ID: 19164226
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT findings in patients with Kikuchi disease.
Kong E; Chun K; Hong Y; Hah J; Cho I
Nuklearmedizin; 2013; 52(3):101-6. PubMed ID: 23681151
[TBL] [Abstract][Full Text] [Related]
11. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT.
Büsing KA; Schönberg SO; Brade J; Wasser K
Nucl Med Biol; 2013 Feb; 40(2):206-13. PubMed ID: 23228852
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
[TBL] [Abstract][Full Text] [Related]
13. Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. A national survey of PET/CT operations in Austria.
Rausch I; Bergmann H; Geist B; Schaffarich M; Hirtl A; Hacker M; Beyer T
Nuklearmedizin; 2014; 53(6):242-8. PubMed ID: 25131649
[TBL] [Abstract][Full Text] [Related]
14. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
15. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
Nanni C; Rossetti V; Zompatori M; Ambrosini V; Montesi V; Mascherini D; Pettinato C; Marzola MC; Colletti PM; Rubello D; Fanti S
Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
19. Supraclavicular lymph nodes detected by 18F-FDG PET/CT in cancer patients: assessment with 18F-FDG PET/CT and sonography.
Lee JH; Kim J; Moon HJ; Cho A; Yun M; Lee JD; Kang WJ
AJR Am J Roentgenol; 2012 Jan; 198(1):187-93. PubMed ID: 22194496
[TBL] [Abstract][Full Text] [Related]
20. Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.
Koopman D; van Dalen JA; Lagerweij MC; Arkies H; de Boer J; Oostdijk AH; Slump CH; Jager PL
J Nucl Med Technol; 2015 Mar; 43(1):21-7. PubMed ID: 25613334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
